Business Context and Reporting Period
This Form 8-K Current Report is filed by IDEAYA Biosciences, Inc. (IDYA) on June 1, 2026. The filing discloses the presentation of complete data from the Phase 2/3 registrational OptimUM-02 trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluates darovasertib in combination with crizotinib for first-line treatment of HLA*A2:01 negative metastatic uveal melanoma (mUM).
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory updates.
Material Changes and Clinical Results
The OptimUM-02 trial met its primary endpoint for the Phase 2 portion, demonstrating statistically significant improvements for the darovasertib combination versus investigator's choice of therapy (ICT):
- Median Progression-Free Survival (PFS): 6.9 months (darovasertib) vs. 3.1 months (ICT) by blinded independent central review (BICR); Hazard Ratio (HR) 0.42 (p < 0.0001).
- Risk Reduction: 58% reduction in risk of disease progression by BICR and 64% by investigator assessment.
- Overall Response Rate (ORR): 37.1% (BICR) and 39.5% (investigator) vs. 5.8% and 1.9% for ICT.
- Disease Control Rate (DCR): 73.3% (BICR) and 74.3% (investigator) vs. 31.1% and 27.2% for ICT.
- Duration of Response: Median 6.8 months.
- Overall Survival (OS): Data remains immature, though an early trend favoring the darovasertib combination was observed.
Guidance, Outlook, and Risks
Regulatory Outlook: The FDA agreed in April 2026 to review the New Drug Application (NDA) under the Real-Time Oncology Review (RTOR) program. The Company completed its first pre-submission in May 2026 and expects to file the NDA in the second half of 2026. Accelerated approval is anticipated based on PFS data, with full approval pending mature OS data.
Safety Profile: The combination was generally well-tolerated. Grade 3/4 treatment-related adverse events occurred in 40.6% of patients (darovasertib) vs. 37.0% (ICT). Discontinuation rates due to adverse events were lower for darovasertib (2.5%) and crizotinib (10.0%) compared to ICT (19.0%).
Risks: Forward-looking statements are subject to risks including clinical trial uncertainties, regulatory approval timing, manufacturing challenges, and competition. The Company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Confirm the timeline for the NDA filing in the second half of 2026 and the FDA's RTOR process status.
- Monitor the pre-specified interim analysis for updated Overall Survival (OS) data required for full approval.
- Review the safety profile details, specifically the incidence of diarrhea, syncope, and hypotension in the darovasertib arm.
- Verify the commercialization strategy and partnership terms with Les Laboratoires Servier.
- Check subsequent filings for any updates on the Phase 3 portion of the trial and enrollment status.